Abstract:Background Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis who had previously had an inadequate response to tumor necrosis factor (TNF) inhibitors. Methods In this 6-month randomized, placebo-controlled, double-blind, phase 3 trial, we randomly assigned 395 patients, in a 2:2:1:1 ratio, to four regimens: 5 mg of tofacitinib administered orally twice daily (132 patients); 10 mg of tofacitinib twice daily (132 patients); placebo, with a switch to 5 mg of tofacitinib twice daily at 3 months (66 patients); or placebo, with a switch to 10 mg of tofacitinib twice daily at 3 months (65 patients). Data from the patients who received placebo during the first 3 months of the trial were pooled. The primary end points were the percentage of patients who had at least 20% improvement according to the criteria of the American College of Rheumatology (ACR20 response) and the change from baseline score on the Health Assessment Questionnaire–Disability Index (HAQ-DI; scores range from 0 to 3, with higher scores indicating greater disability) at the month 3 analysis. Results At 3 months, the rates of ACR20 response were 50% with the 5-mg dose of tofacitinib and 47% with the 10-mg dose, as compared with 24% with placebo (P<0.001 for both comparisons); the corresponding mean changes from baseline in HAQ-DI score were −0.39 and −0.35, as compared with −0.14 (P<0.001 for both comparisons). Serious adverse events occurred in 4% of the patients who received the 5-mg dose of tofacitinib continuously and in 6% who received the 10-mg dose continuously. Over the course of 6 months, there were four serious infections, three herpes zoster infections, one myocardial infarction, and one ischemic stroke among the patients who received tofacitinib continuously. Elevations of aspartate and alanine aminotransferase concentrations of three or more times the upper limit of the normal range occurred in more patients who received tofacitinib continuously than in patients who received placebo followed by tofacitinib. Conclusions In this trial involving patients with active psoriatic arthritis who had had an inadequate response to TNF inhibitors, tofacitinib was more effective than placebo over 3 months in reducing disease activity. Adverse events were more frequent with tofacitinib than with placebo. (Funded by Pfizer; OPAL Beyond ClinicalTrials.gov number, NCT01882439 .) Supported by Pfizer. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank the patients, investigators, and study teams involved in OPAL Beyond; and Amanda Pedder of Complete Medical Communications for providing medical writing support. Source Information From the University of Toronto, Toronto Western Hospital, Toronto (D.G.); Geisel School of Medicine at Dartmouth, Dartmouth–Hitchcock Medical Center, Lebanon, NH (W.R.); Universidade Federal do Paraná, Curitiba, Brazil (V.F.A.); Goethe University and Fraunhofer Institute for Molecular Biology and Applied Ecology Project Group Translational Medicine and Pharmacology (TMP), Frankfurt, Germany (F.B.); Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Marqués de Valdecilla, Santander, Spain (R.B.); Specjalistyczne Gabinety Lekarskie DERMED, Lodz, Poland (A.K.); Pfizer, Groton, CT (E.K., C.W., S.M., K.S.K.); and Pfizer, Collegeville, PA (T.H.). Address reprint requests to Dr. Gladman at Toronto Western Hospital, 399 Bathurst St., Suite 1E0-410B, Toronto, ON M5T 2S8, Canada, or at dafna.gladman@utoronto.ca . Access this article: <a href="/action/clickThrough?id=1071&url=%2Faction%2FcdfProxy%3Faction%3Dsubscribe%26url%3Dhttp%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1615977%253Frss%253DsearchAndBrowse%26promo%3DONFGNSB1&loc=%2Fdoi%2 -Abstract Truncated-

Tofacitinib With Conventional Synthetic Disease-Modifying Antirheumatic Drugs In Chinese Patients With Rheumatoid Arthritis: Patient-Reported Outcomes From A Phase 3 Randomized Controlled Trial

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis

THU0215 Effects of Tofacitinib on Patient-Reported Outcomes in a Phase 3 Study of Chinese Patients with Active Rheumatoid Arthritis and an Inadequate Response to Dmards

AB0514 Efficacy and Safety of Tofacitinib in Chinese Patients with Active Rheumatoid Arthritis: Subgroup Analysis from a Phase 3 Study of Tofacitinib in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs

Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): an Open-Label Randomized Controlled Trial.

Efficacy and Safety of Tofacitinib in Chinese Patients with Active Psoriatic Arthritis: a Phase 3, Randomised, Double-Blind, Placebo-Controlled Study

The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study

A retrospective study of efficacy of tofacitinib combined with bDMARDs in the treatment of rheumatoid arthritis patients with inadequate response to bDMARDs

Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial

Tofacitinib treatment for plaque psoriasis and psoriatic arthritis: A meta-analysis of randomised controlled trials

Exposure–Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results from Two Phase 3 Studies

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response

Tofacitinib therapy in systemic lupus erythematosus with arthritis: a retrospective study

[Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis]

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III Study

Tofacitinib in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active Rheumatoid Arthritis

Comparative effectiveness of tofacitinib and tumour necrosis factor inhibitors in patients with rheumatoid arthritis in real-world practice: a prospective observational study

Liver Function Changes in Rheumatoid Arthritis Patients Treated with Tofacitinib: Systematic Review